Prospective Bladder Cancer Infrastructure Nationwide Research Network for Observational and Interventional Bladder Cancer Studies
Led by Prospective Bladder Cancer Infrastructure Foundation · Updated on 2026-09-21
3600
Participants Needed
23
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to create a nationwide group of bladder cancer patients in the Netherlands, including those with high-risk non-muscle-invasive, muscle-invasive, and metastatic stages. It focuses on gathering information to support both observational and interventional bladder cancer research. The study is sponsored by the Prospective Bladder Cancer Infrastructure Foundation and includes adults diagnosed with bladder cancer at any stage except Ta.
Participants are observed over a long period, with no specific treatments or interventions assigned by the study. The infrastructure supports collecting data to study overall survival over 10 years as the primary outcome. Secondary outcomes include progression-free survival, recurrence-free survival over 10 years, and health-related quality of life assessments for 2 years.
During the study, participants will have their health and cancer status monitored, and quality of life will be evaluated. Data collection may involve questionnaires and medical records over the study period. The study plans to follow participants until the end date in 2041, with a primary completion date set for the end of 2040.
CONDITIONS
Brief Title
Prospective Bladder Cancer Infrastructure (ProBCI)
Research Team
A
A. Richters, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Prospective Bladder Cancer Infrastructure Foundation
Lead Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Diagnosed with bladder cancer
Cancer stage other than Ta
18 years or older
Able to provide written informed consent
You will not qualify if you...
No exclusion criteria
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - Up to 21 years
Participants are observed and their health information is collected over time to support bladder cancer research.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Bladder-Sparing Treatment Approach for Large Non-Muscle-Invasive Bladder Cancer
Comparing Maximal TURBT with Chemotherapy and Immunotherapy Versus Immediate Radical Cystectomy
Phase 12 Study Evaluating Intravesical MK-3120 for High-Risk Non-Muscle Invasive Bladder Cancer After Tumor Removal
Phase 3 Study Comparing Sacituzumab Tirumotecan to Non-Platinum Chemotherapy in Advanced Urothelial Cancer
Phase 1 Study of Intratumoral ONM-501 Alone and with Cemiplimab for Advanced Solid Tumors and Lymphomas
Get Moving Trial Evaluating Home-Based Prehabilitation Exercise Using ExerciseRx App
for Bladder and Upper Tract Urothelial Cancer Patients Undergoing Surgery
Long-Term Study of Urothelial and Rare Genitourinary Tract Cancers to Understand Disease Progression and Treatment Responses
Validating a New Multiplex ELISA Urine Test for Detecting Bladder Cancer
in Adults with Microscopic Hematuria
Non-Invasive Multiplex ELISA Test to Monitor Patients with a History of Bladder Cancer
Evaluating Personalized Chemotherapy for Bladder Cancer Using Organoid Technology
A Study Comparing Organoid-Guided Drug Sensitivity and BCG Treatment
For Adults Aged 18 to 80 with Non-Muscle Invasive Bladder Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCI.